Abilita Therapeutics Inc.
San Diego, CA
- UEI
- DEYUQFS2MLT5
- CAGE
- 77UL8
- Primary NAICS
- Not on record
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 5785 Oberlin Dr #100, San Diego, CA 92121, USA
- Website
- abilitabio.com
- Founded
- 2014
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 51 Wholesale Trade – Nondurable Goods
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Grant awards
Similar vendors
About the company
Abilita Therapeutics Inc. is a biotechnology company focused on discovering drugs targeting membrane proteins like G protein-coupled receptors (GPCRs) and ion channels, utilizing its proprietary Enabled Membrane Protein (EMP) technology. As stated on its website, Abilita Bio is "Leading biotech discovering drugs targeting membrane proteins like GPCRs & ion channels, unlocking therapeutic potential with EMP™ technology."
Through federal grant awards from agencies like the National Cancer Institute and National Institute on Aging, Abilita Therapeutics has provided innovative research services and therapeutic development programs targeting challenging disease areas. One major award involved developing a novel anti-CCR8 single-domain antibody (VHH) for treating non-small cell lung cancer, funded by the NCI's Cancer Treatment Research program. The company leveraged its EMP technology to generate stabilized CCR8 variants as antigens, enabling the discovery of VHH antibodies targeting the transmembrane core of the wild-type human CCR8 receptor. Another NIA-funded project aimed to discover blood-brain barrier (BBB) targeting antibodies for Alzheimer's disease treatment by utilizing the EMP platform to develop single-domain antibodies that can latch onto BBB transporters and facilitate drug delivery to the brain. Additionally, Abilita received an NIA grant to discover therapeutic nanobodies targeting GPCRs in the brain for Alzheimer's disease treatment.
Quick answers
Is Abilita Therapeutics Inc. registered in SAM.gov?
Yes. Abilita Therapeutics Inc.'s SAM.gov registration is active through October 4, 2027.
What is Abilita Therapeutics Inc.'s most recent federal award?
Abilita Therapeutics Inc.'s most recent federal grant award is Novel anti-CCR8 VHH for the treatment of nsclc (R43CA281478), from National Cancer Institute (NIH), on September 15, 2023.
On GovTribe
See Abilita Therapeutics Inc.'s full federal record
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors